Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Regor Therapeutics Group, a clinical-stage global biopharmaceutical company,  announced a strategic collaboration to optimize Regor's proprietary, cutting-edge rCARD™ (Regor Computer Accelerated Rational Discovery) platform for identification of novel targets and therapeutics that fulfill unmet patient clinical needs and preferences in the breast oncology arena.

The partnership will unite the key core competencies of both organizations to leverage expertise from early discovery through preclinical, clinical, and commercial launch, resulting in treatments that deliver on the promise of fulfilling on efficacy but also developing therapies with tolerability and quality of life profiles that are aligned with patient priorities and concerns.

With a Phase 3 asset – oral lasofoxifene – in development for the treatment of ESR1-mutated ER+ HER2- mBC, the Sermonix team has expertise within the clinical drug development and commercialization arena and understands the landscape and value proposition of new treatments, which are requirements for launch success and adoption by both patients and health care providers.

Patient insights and unmet needs within the arena of onco-sexuality and cardio oncology, in addition to patient concerns with respect to bone health, have been increasing in importance and are areas for which Sermonix also has expertise and interest in exploring. These areas are currently gaps within the breast cancer treatment patient arena and hold great concern for patients as breast cancer potentially evolves from a lethal to a chronic disease.

Regor's leading rCARD™ platform empowers drug discovery and development from target identification and validation, molecular design and optimization, to translational research and clinical development with unprecedented speed, efficiency, and success rate.

"Regor's translational to clinical approach – and then confirmation of clinical impact – is one we greatly admire and is producing molecules for development that will be best in class from both an efficacy and tolerability perspective," said Dr. David Portman, Sermonix founder and chief executive officer. "At Sermonix, we believe patients deserve not only highly efficacious treatments, but also ones that are well tolerated and potentially improve quality of life for breast cancer patients. Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone, and cardiovascular health would be fulfilling on the promise of optimized drug development. It is an honor to collaborate with Regor in that shared mission."

Sermonix is currently enrolling its Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-3) study, comparing targeted lasofoxifene in combination with the CDK 4/6 inhibitor abemaciclib versus fulvestrant plus abemaciclib in pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation.

"After engaging in extensive discussions with Sermonix, closely watching its clinical and commercial market development efforts in the breast oncology segment, it is obvious the company shares the vision and dedication of our team at Regor," said Dr. Xiayang Qiu, founder and CEO of Regor. "The Sermonix team demonstrates both expertise and passion, and we are truly excited to embrace that as part of our work in identifying optimal drug candidates that can make a significant impact for patients with metastatic breast cancer."